HASBROUCK HEIGHTS, N.J., May 11, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that an informative interview and presentation was released on Grand Rounds in Urology, a highly respected and authoritative urologic professional community, and host of international conferences and symposia that bring together the top thought leaders in the treatment of urologic disease, with meetings that focus on current best treatment practices as well as future trends and directions. Grand Rounds in Urology is hosted and edited by Dr. E. David Crawford of the University of Colorado. Dr. Crawford is an international expert in urological research who is a Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado, Denver CO. The presentation was given by Dr. Ronald Tutrone Jr., MD FACS of Chesapeake Urology Research Associates, Towson, MD. Dr. Tutrone has been Principal Investigator in more than 200 clinical research trials. He is Chairman of the William E. Kalhert Endowment for Urological Research and Medical Director of Chesapeake Urology Research Associates. Dr Tutrone has extensive experience with Nymox's Fexapotide drug.
The link to the presentation is https://grandroundsinurology.com/fexapotide-for-bph/.
Nymox's Fexapotide has been shown to produce long-term improvements in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH), a problem that afflicts an estimated 100 million or more men in the world. Fexapotide does not cause the annoying side effects and risks found with available treatments for BPH and has also been shown to lower the occurrence of surgery for BPH. Fexapotide is also in development for low grade prostate cancer.
For more information please contact firstname.lastname@example.org or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2017, and its Quarterly Reports.
For Further Information Contact:
Nymox Pharmaceutical Corporation